Neurocrine Biosciences Inc (NBIX)
Current ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total current assets | US$ in thousands | 1,607,000 | 1,649,900 | 1,496,600 | 1,432,800 | 1,453,500 | 1,205,500 | 1,019,300 | 1,018,200 | 972,800 | 1,005,700 | 1,110,100 | 1,085,400 | 1,016,200 | 1,156,900 | 1,146,200 | 968,200 | 831,000 | 819,232 | 748,808 | 633,192 |
Total current liabilities | US$ in thousands | 654,800 | 691,600 | 582,500 | 374,100 | 537,700 | 485,100 | 285,700 | 253,500 | 245,800 | 225,900 | 212,900 | 190,000 | 186,500 | 611,000 | 573,000 | 140,300 | 565,300 | 115,652 | 100,589 | 72,003 |
Current ratio | 2.45 | 2.39 | 2.57 | 3.83 | 2.70 | 2.49 | 3.57 | 4.02 | 3.96 | 4.45 | 5.21 | 5.71 | 5.45 | 1.89 | 2.00 | 6.90 | 1.47 | 7.08 | 7.44 | 8.79 |
December 31, 2023 calculation
Current ratio = Total current assets ÷ Total current liabilities
= $1,607,000K ÷ $654,800K
= 2.45
The current ratio of Neurocrine Biosciences, Inc. has displayed fluctuating trends over the past eight quarters. The ratio ranged from a low of 2.39 in Q3 2023 to a high of 4.02 in Q1 2022, indicating variability in the company's short-term liquidity position.
In general, a current ratio above 1.0 indicates that a company has more current assets than current liabilities, suggesting a strong ability to meet its short-term obligations. Neurocrine Biosciences, Inc.'s current ratio has consistently been above 1.0 across all quarters, reflecting a positive liquidity position.
The quarter with the highest current ratio was Q1 2022 at 4.02, suggesting that the company had a strong ability to cover its current liabilities with its current assets during that period. On the other hand, the lowest current ratio was observed in Q3 2023 at 2.39, implying a relatively lower liquidity position compared to other quarters.
Overall, while the current ratio of Neurocrine Biosciences, Inc. has fluctuated over the past two years, it has generally remained above 1.0, indicating a relatively healthy short-term liquidity position.
Peer comparison
Dec 31, 2023